The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Inflammatory biomarkers for prediction of tumor responses and adverse events in non-small cell lung cancer patients treated with anti-PD-1 inhibitor.
 
Norikazu Matsuo
No Relationships to Disclose
 
Koichi Azuma
No Relationships to Disclose
 
Satoshi Hattori
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Takeda
 
Akihiko Kawahara
No Relationships to Disclose
 
Hidenobu Ishii
No Relationships to Disclose
 
Takaaki Tokito
No Relationships to Disclose
 
Kazuhiko Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Lilly Japan (Inst)
 
Yuji Shibata
No Relationships to Disclose
 
Tadasuke Shimokawaji
Honoraria - AstraZeneca; Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Tetsuro Kondo
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Haruhiro Saito
No Relationships to Disclose
 
Kouzo Yamada
No Relationships to Disclose
 
Tetsuro Sasada
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Sharp & Dohme; Ono Pharmaceutical
Research Funding - BrightPath Biotheraputics; Taiho Pharmaceutical
 
Tomoaki Hoshino
No Relationships to Disclose